SALT LAKE CITY, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEXIA, Myriad's ninth molecular diagnostic product, is the second product launched by the Company this year.
